Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study Identifies Novel Drug Target in DLBCL, MCL

Publish date:: December 5, 2019

Key clinical point: Pre-clinical data suggests maternal embryonic leucine zipper kinase (MELK) may be a novel drug target in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

Major finding: In cellular studies, the MELK inhibitor OTSSP167 demonstrated strong anti-cancer activity in several lymphoma cell lines.

Study details: A pre-clinical study examining the effects of MELK as a novel drug target in DLBCL and MCL.

Disclosures: The authors reported having no conflicts of interest.

Citation:

Maes A et al. Blood Cancer J. 2019 Nov 18. doi: 10.1038/s41408-019-0249-x.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,